Dose-Dependent Regulation of Alternative Splicing by MBNL Proteins Reveals Biomarkers for Myotonic Dystrophy

被引:65
|
作者
Wagner, Stacey D. [1 ]
Struck, Adam J. [1 ]
Gupta, Riti [2 ]
Farnsworth, Dylan R. [3 ]
Mahady, Amy E. [1 ]
Eichinger, Katy [4 ]
Thornton, Charles A. [4 ]
Wang, Eric T. [5 ,6 ,7 ]
Berglund, J. Andrew [1 ,7 ]
机构
[1] Univ Oregon, Inst Mol Biol, Dept Chem & Biochem, Eugene, OR 97403 USA
[2] Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA
[3] Univ Oregon, Inst Mol Biol, Dept Biol, Eugene, OR 97403 USA
[4] Univ Rochester, Med Ctr, Dept Neurol, Rochester, NY 14642 USA
[5] MIT, Dept Biol, Cambridge, MA 02139 USA
[6] MIT, Koch Inst Integrat Canc Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA
[7] Univ Florida, Dept Biochem & Mol Biol, Ctr NeuroGenet, Gainesville, FL 32610 USA
来源
PLOS GENETICS | 2016年 / 12卷 / 09期
关键词
MESSENGER-RNA; CTG REPEAT; NUCLEAR-LOCALIZATION; EXPRESSION; CELF; TRANSCRIPTOME; EXPANSION; DESIGN; REGION; LENGTH;
D O I
10.1371/journal.pgen.1006316
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Alternative splicing is a regulated process that results in expression of specific mRNA and protein isoforms. Alternative splicing factors determine the relative abundance of each isoform. Here we focus on MBNL1, a splicing factor misregulated in the disease myotonic dystrophy. By altering the concentration of MBNL1 in cells across a broad dynamic range, we show that different splicing events require different amounts of MBNL1 for half-maximal response, and respond more or less steeply to MBNL1. Motifs around MBNL1 exon 5 were studied to assess how cis-elements mediate the MBNL1 dose-dependent splicing response. A framework was developed to estimate MBNL concentration using splicing responses alone, validated in the cell-based model, and applied to myotonic dystrophy patient muscle. Using this framework, we evaluated the ability of individual and combinations of splicing events to predict functional MBNL concentration in human biopsies, as well as their performance as biomarkers to assay mild, moderate, and severe cases of DM.
引用
收藏
页数:24
相关论文
共 50 条
  • [1] Splicing Biomarkers of Disease Severity in Myotonic Dystrophy
    Nakamori, Masayuki
    Sobczak, Krzysztof
    Puwanant, Araya
    Welle, Steve
    Eichinger, Katy
    Pandya, Shree
    Dekdebrun, Jeannne
    Heatwole, Chad R.
    McDermott, Michael P.
    Chen, Tian
    Cline, Melissa
    Tawil, Rabi
    Osborne, Robert J.
    Wheeler, Thurman M.
    Swanson, Maurice S.
    Moxley, Richard T., III
    Thornton, Charles A.
    ANNALS OF NEUROLOGY, 2013, 74 (06) : 862 - 872
  • [2] Modulatory role of RNA helicases in MBNL-dependent alternative splicing regulation
    Taylor, Katarzyna
    Piasecka, Agnieszka
    Kajdasz, Arkadiusz
    Brzek, Aleksandra
    Espinoza, Micaela Polay
    Bourgeois, Cyril F.
    Jankowski, Artur
    Borowiak, Malgorzata
    Raczynska, Katarzyna D.
    Sznajder, Lukasz J.
    Sobczak, Krzysztof
    CELLULAR AND MOLECULAR LIFE SCIENCES, 2023, 80 (11)
  • [3] Alternative splicing of myomesin 1 gene is aberrantly regulated in myotonic dystrophy type 1
    Koebis, Michinori
    Ohsawa, Natsumi
    Kino, Yoshihiro
    Sasagawa, Noboru
    Nishino, Ichizo
    Ishiura, Shoichi
    GENES TO CELLS, 2011, 16 (09) : 961 - 972
  • [4] Correction of Clcn1 alternative splicing reverses muscle fiber type transition in mice with myotonic dystrophy
    Hu, Ningyan
    Kim, Eunjoo
    Antoury, Layal
    Wheeler, Thurman M.
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [5] Alternative splicing dysregulation across tissue and therapeutic approaches in a mouse model of myotonic dystrophy type 1
    Hicks, Sawyer M.
    Frias, Jesus A.
    Mishra, Subodh K.
    Scotti, Marina
    Muscato, Derek R.
    Valero, M. Carmen
    Adams, Leanne M.
    Cleary, John D.
    Nakamori, Masayuki
    Wang, Eric
    Berglund, J. Andrew
    MOLECULAR THERAPY NUCLEIC ACIDS, 2024, 35 (04):
  • [6] Model for Alternative Splicing of Insulin Receptor in Myotonic Dystrophy Type 1
    Tonevitsky, E. A.
    Trushkin, E. V.
    BULLETIN OF EXPERIMENTAL BIOLOGY AND MEDICINE, 2009, 147 (06) : 772 - 776
  • [7] An Overview of Alternative Splicing Defects Implicated in Myotonic Dystrophy Type I
    Lopez-Martinez, Andrea
    Soblechero-Martin, Patricia
    de-la-Puente-Ovejero, Laura
    Nogales-Gadea, Gisela
    Arechavala-Gomeza, Virginia
    GENES, 2020, 11 (09) : 1 - 27
  • [8] MBNL-dependent impaired development within the neuromuscular system in myotonic dystrophy type 1
    Tahraoui-Bories, Julie
    Merien, Antoine
    Gonzalez-Barriga, Anchel
    Laine, Jeanne
    Leteur, Celine
    Polveche, Helene
    Carteron, Alexandre
    De Lamotte, Juliette Duchesne
    Nicoleau, Camille
    Polentes, Jerome
    Jarrige, Margot
    Gomes-Pereira, Mario
    Ventre, Erwann
    Poydenot, Pauline
    Furling, Denis
    Schaeffer, Laurent
    Legay, Claire
    Martinat, Cecile
    NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2023, 49 (01)
  • [9] Ribonuclear inclusions and MBNL1 nuclear sequestration do not affect myoblast differentiation but alter gene splicing in myotonic dystrophy type 2
    Cardani, Rosanna
    Baldassa, Simona
    Botta, Annalisa
    Rinaldi, Fabrizio
    Novelli, Giuseppe
    Mancinelli, Enzo
    Meola, Giovanni
    NEUROMUSCULAR DISORDERS, 2009, 19 (05) : 335 - 343
  • [10] Genome Wide Identification of Aberrant Alternative Splicing Events in Myotonic Dystrophy Type 2
    Perfetti, Alessandra
    Greco, Simona
    Fasanaro, Pasquale
    Bugiardini, Enrico
    Cardani, Rosanna
    Manteiga, Jose M. Garcia
    Riba, Michela
    Cittaro, Davide
    Stupka, Elia
    Meola, Giovanni
    Martelli, Fabio
    PLOS ONE, 2014, 9 (04):